VC investment in financial turmoil, caution CRO-VC-pharmaceutical industries – B

Financial Di quiet storm past the hustle and bustle of the VC, the venture capital, whether public offering or private, are on a more cautious investment CRO.

And medical and health industry recently, after catching up IT Industry to become the most popular VC investment in different sectors of the situation, the reporter recently held in Hangzhou, China International Investment biopharmaceutical outsourcing services to the General Assembly felt that the Environment Forum, VC investment in the CRO business is very cautious, even pessimistic.

VC preference for large CRO As the China International Conference biopharmaceutical outsourcing services last agenda, investment environment, high popular forum. The forum attracted a total of

including Fidelity Asia, Martin Currie China, Morningside Ventures, Ignition Partners and other domestic and foreign venture capital scene. Meeting the investment community and the Chinese Fonda, Charles Shi Rui Chinese people and other domestic CRO company, Merck, GlaxoSmithKline And other representatives of multinational companies, as well as from the Hangzhou Economic and Technological Development Zone, Suzhou Industrial Park, representatives of government departments around the international financial crisis on investment of CRO, CRO services, investment needs and return expectations of investors, as well as through strategic partnerships Cooperation Construction industries and development zones of international CRO CRO services supporting construction to promote the exchange of such topics in depth.

According to the will of the experts, the annual global pharmaceutical market Sell Amount of about 500 billion U.S. dollars, in general, pharmaceutical R & D will account for 10%, for China's CRO, the future of the space up more than expected to reach 10 billion U.S. dollars.

From China Pharmaceutical Industry Management Association and the National Association of CRO medical technology market data from the Commonwealth, the global biopharmaceutical outsourcing industry at an average annual growth rate of 13.7%. In recent years, the Chinese in this area at an average annual rate of 25% of the rapid development of the scale of last year reached 40 billion, is one of the fastest growing countries. In less than 10 years, China has emerged more than 1,000 enterprises engaged in CRO.

Such a high-growth industries will naturally attract domestic and foreign venture capital concern. However, the VC this to be representative of how much so eager to get from the capital market, "rocket boosters" of small and medium sized CRO company disappointed.

"We think CRO industry to go very far, very successful in the end will not be more than 5, which is why we like to walk in front of the accounting industry leading cause of large companies. This is an investment The focus in mind. "Martin Currie China's health care fund, said General Manager Chen Yunru is.

As an investment in Greater China health care industry, health and life sciences industry long-term capital appreciation fund, the total capital reached 200 million U.S. dollars advance. The 5-year closed fund of up to 30% of the fund for private equity. According to Chen Yun introduction, Martin Currie Investment in China has been the domestic CRO business.

"Wuxi WuXi PharmaTech Market, we also conducted its investigation, it was a very far-sighted investment. I personally think that CRO company from an investment point of view to have a certain size. CRO small companies that view may be somewhat disappointed, but the fact is true?? Go ahead in the industry and have a certain size CRO company in attracting VC will have an advantage. CRO companies to small, it must have its own special resources, rather than large and comprehensive, large and comprehensive features that are persistent Quemei can not. "Chen Yun said.

Morningside Ventures speech to domestic CRO many small companies even more disappointed. The biomedical venture capital company manager MichaelXue even said that China CRO market to this end, three major companies have already accounted for in this market very full. Financing is still awkward

small CRO

Market statistics in accordance with earlier data, with the domestic economy is getting warmer, the new round of investment boom coming forward bio-pharmaceutical industry quietly.

The e-commerce company in China offers quality products such as Bandage manufacturer , china foam cervical collar, and more. For more , please visit finger splint@cervical collar suppliersc today!

Processing your request, Please wait....

Leave a Reply